Theme: Breakthroughs and Achievements in Neurocognitive Research

Neurocognitive Disorders 2016

Neurocognitive Disorders 2016

Neurocognitive Disorders 2016 International Conferences invites all the participants from all over the world to attend the prestigious Scientific Conference on Cognitive Disorders during November,07-08, 2016 in Barcelona, Spain  which encompass Keynote presentations, Oral Presentation, Poster presentations and Exhibitions  

Neurocognitive Disorders 2016  is a global platform to discuss and learn about early detection as well as treatment, care based on Professional standards, and increased research to accomplish cure for all cognitive Disorders.  The conference includes leading international experts in Neurocognitive Disorders hospitals specialists, doctors, research scholars and general practitioners form all over the world.

Neurocognitive disorders can affect memory, concentration, Knowledge, language, view, and social cognition. They interfere extremly with a person’s everyday independence in Major Neurocognitive Disorder, but not so in Minor Neurocognitive Disorder.

Track 1: Neurodegenerative disorders:

Neurodegenerative disorders are defined by the progressive decline of neuronal functions in a spatiotemporal fashion, which leads to intensifying neurological symptoms, in some cases, with devastating speed. This is accompanied by the steady intensity of neuropathological findings from more to less affected regions in the nervous system. The molecular pathway driving constant decline of disease symptoms and pathology is not yet understood. However, the enlargement of pathological protein assemblies, spreading from cell-to-cell, may well explain these phenomena.

We will bring neurologists and   neuropathologists basic scientists from a wide variety of neurodegenerative diseases to discuss the conclusion of these mechanisms for building disease models and therapeutic strategies. We will also speak about the similarities and differences between the different classes of neurodegeneration, comparing to prototypical prion diseases.

Track 2: Neurocognitive Disorder:

Neurocognitive disorders include delirium, mild cognitive impairment and dementia which are characterized by decline from an attained level of cognitive functioning. The disorders have diverse clinical characteristics and aetiologies, with Alzheimer disease, frontotemporal degeneration, cerebrovascular disease, Lewy body disease, traumatic brain injury, infections, and alcohol abuse showing common causes. 

A neurocognitive deficit is a reduction or impairment of cognitive function, but mainly when physical changes can be seen to have occurred in brain, such as after neurological and mental illness, drug use, or brain injury.

Clinical neuropsychologist use neuropsychological tests to detect and understand such deficits and may be involved in the rehabilitation of an affected person. This discipline that studies neurocognitive deficits to infer normal psychological function is known as cognitive neuropsychology.

Track 3: Vascular Disorder:

Neurovascular disorders affect the cerebral vascular system and the spinal cord that encompasses any abnormality of the blood vessels supplying the brain and spine. Abnormalities may be narrowing of arteries which reduce blood flow to the brain that tends to risk of Stroke and weakening of arteries that leads brain aneurysms and increase the risk of intracranial bleeding. Very common Neurovascular Diseases are brain aneurysms, stroke, arteriovenous malformations, spinal vascular malformations, carotid stenosis, cerebral hemorrhage,   intracranial atherosclerosis, Vasculitis etc. 

Usually, people having a stroke will be having the sudden onset of weakness or numbness on one side of their body. They may also have difficulty in seeing or speaking, or feel a loss of balance or coordination. Sometimes people will have only mild symptoms that will totally resolve. For example, they may feel weak or clumsy in one hand, but then it goes away several minutes later. They may suddenly lose vision in one eye, but after a short time it completely returns to normal. They may ignore it but it’s a warning sign. That’s a transient ischemic attack, and it’s a caution that they are at risk for a large stroke in the future.

This session includes Diagnostic Neuropsychology and Neuroimaging, HIV-Associated Neurocognitive Disorders, Frontotemporal dementia etc.

Track 4: Traumatic Injury:

Traumatic brain injury takes place when an external mechanical force causes brain dysfunction. Traumatic brain injury usually the results from a violent blow or jolt to the head or body. An object penetrating the skull, such as a bullet or shattered piece of skull, also can cause traumatic brain injury.

We will be addressing Neurogenesis of brain development, Cerebral metabolic dysfunction, Paralysis, Aging and Neurodegeneration, Brain research , Anti-amyloid therapy  in this particular session

Track 5: Dementia:

Alzheimer’s is very common cause of dementia among older adults. Dementia is the loss of cognitive functioningthinking, reasoning, remembering, and behavioral abilities to such an extent that it interferes with a person’s daily life activities. Dementia also ranges in severity from the mildest stage, when it is just beginning to affect a person’s functioning, to the last stage, when the person must depend completely on others for basic activities of daily living.

The causes of dementia can vary, depending on the types of brain changes that may be taking place. Other dementias include Lewy body dementia, vascular dementia, and also frontotemporal disorders. It is common for people to have mixed dementia—a combination of more disorders, at least one of which is dementia. For example, some people have both Alzheimer's disease and vascular dementia.

It also includes Alcohol addiction and mental health, Metabolic syndrome and Alzheimer’s disease, Drug treatment and therapies

Track 6:Substance Abuse:

There is substantial clinical need to recognize the individuals who need care for cognitive issues that go beyond normal aging. These problems are noticeable, but clinicians have lacked a reliable diagnosis by which to assess symptoms the most proper treatment or services. Recent studies suggest that identifying mild neurocognitive disorders in the early stages itself may allow interventions to be more effective. Early intervention efforts may enable the use of treatments that are ineffective at more severe levels of impairment and may prevent or slow progression. Researchers will analyze how well the new diagnostic criteria address the symptoms, as well as potential therapies like educational or brain stimulation.

Major neurocognitive disorder was previously known as dementia and the primary feature of all neurocognitive disorders is an acquired cognitive decline in one or more cognitive domains. Neurocognitive disorders can affect memory, concentration, Knowledge, language, perception, and social cognition. 

Track 7:Neuro Pharmaceutics:

Neuro-pharmaceutics focuses on discovery of therapeutic targets, and then translating those discoveries into drug and therapy development. Neuropharmaceutics is the largest potential growth sector of the pharmaceutical industry. However, this growth is blocked by the problem of the blood-brain barrier

ConferenceSeries Ltd invites all the participants from all over the world to attend ‘Neurocognitive Disorders 2016 during November 07-08, 2016 at Barcelona, Spain which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions.

Neurocognitive disorders includes Alzheimer’s disease, is one of the biggest global public health challenges facing our generation. Worldwide, at least 46 million people are living with dementia this number is expected to double by 2030 and more than triple by 2050 to 116 million. Much of the increase will be in developing countries like Western Europe and North America. Already 62% of people with dementia live in developing countries. Today, over 35 million people worldwide currently live with the condition. This number is expected to double by 2030 and more than triple by 2050 to 116 million. No treatments available to slow or stop the brain damage caused by Alzheimer’s disease, several medications can temporarily help improve the symptoms of dementia for some people. In two decades, it is estimated that 1.4 million Canadians will have dementia, costing the economy almost $300 billion per year. Globally, dementia cost $600 billion a year.

The term Dementia describes a loss of mental ability (cognitive impairment) associated with gradual death of brain cells. Vascular Dementia can be caused by a number of different diseases, usually neurodegenerative diseases, such as Alzheimer's disease, front temporal dementia and dementia with Lewy bodies. Vascular dementia is caused when the brain's blood supply is restricted or stopped, leading brain cells to die.

Delirium is defined as a transient, usually reversible, cause of cerebral dysfunction and manifests clinically with a wide range of neuropsychiatric abnormalities. It can occur at any age, but it occurs more commonly in patients who are elderly and have compromised mental status.

Delirium occurs in 30% of those in emergency departments. Occurrence rates vary from 11-42% and it is the most common complication of hospitalization in the elderly population. The incidence is also higher in those with pre-existing cognitive impairment. The prevalence is higher in patients with malignancy and HIV. Despite these facts, delirium remains underdiagnosed and poorly managed - only 20-50% are recognized by healthcare professionals.

Why to attend?

Neurocognitive disorders 2016 will provide an opportunity for all stakeholders working on Alzheimer’s disease and Dementia to talk about their work. Neurocognitive disorders will congregate renowned speakers, principal investigators, experts, neurologist’s and Dementia researchers from both academia and health care industry will join together to discuss their views and research. The conference will be comprised of sessions by world class experts in the field of neurology. In Neurocognitive disorders international symposiums, B2B meetings, international workshops will also be organized to discuss the specific topics in the field of Dementia and Neurology.

Target Audience:

  • Neurologists and Directors
  • Physicians
  • Neuroscientists
  • Specialists
  • researchers
  • Health care professionals
  • Professors
  • Industrial Experts
  • Neurosurgeons
  • Psychiatrist
  • Nutritional Scientists
  • Lecturers and Students from Academia in the study of Dementia
  • Students from Academia in the research of Neurology

It is our pleasure to welcome you to the Neurocognitive disorders 2016 to be held in Barcelona, Spain from November 07-08, 2016.

The organizing committee is gearing up for an exciting and informative program on a variety of topics, poster presentations and various programs for participants from all over the world. Unsurpassed substantiation cure for Neurocognitive disorders clearly shows that the close association of families and careers in the care of their loved ones is key to improving early revealing of Vascular Dementia, renewal to a healthy  weight and sustaining long term wellbeing.

This conference will increase knowledge, provide support, assist learning and allow to seek out applicable services and to develop the best environment to support recovery from these complex and devastating diseases.

Importance and Scope:

The United Nations projects that the number of individuals with dementia in developed countries alone will be approximately 36.7 million by the year 2050. Changing demographics have underscored the necessity to develop similar approaches for the remediation of the cognitive impairment associated with more benign syndromes, such as mild cognitive impairment (MCI) and age-associated cognitive decline (AACD)

Alzheimer’s disease is the most common form of dementia accounting for 50% to 70% of all cases. Currently, there are an estimated 4 million individuals with dementia in the USA with more than 100 000 deaths annually, with France, Italy, and England having close to 1 million cases each,2 and in Greece there are 200 000 cases. 9 AD is a progressive, neurodegenerative disorder, characterized ncuropathologically by widespread neuronal loss, presence of neurofibrillary tangles, and deposits of β-amyloid in cerebral blood vessels and neuritic plaques.

Dementia is widely considered the second most common cause of dementia after Alzheimer's disease, accounting for 10 percent of cases. Many experts believe that vascular dementia remains underdiagnosed like Alzheimer's disease even though it's recognized as common.

Delirium is defined as a transient, usually reversible, cause of cerebral dysfunction and manifests clinically with a wide range of neuropsychiatric abnormalities. It can occur at any age, but it occurs more commonly in patients who are elderly and have compromised mental status.

Delirium occurs in 30% of those in emergency departments. Occurrence rates vary from 11-42% and it is the most common complication of hospitalization in the elderly population. The incidence is also higher in those with pre-existing cognitive impairment. The prevalence is higher in patients with malignancy and HIV. Despite these facts, delirium remains underdiagnosed and poorly managed - only 20-50% are recognized by healthcare professionals.

Amnestic Disorders are a group of disorders that involve loss of memories previously established, loss of the ability to create new memories, or loss of the ability to learn new information.1 In general, Amnestic Disorders are caused by structural or chemical damage to parts of the brain.

People who suffer from Amnestic Disorders usually experience difficulty recalling events that happened in the past or facts they have learned prior to diagnosis. This type of amnesia is known as retrograde amnesia. Some people may also experience symptoms of anterograde amnesia, which involves the inability to learn new facts or retain new memories.

Alzheimer's Research UK currently funds 150 research projects across the UK and has committed nearly £40million to dementia research.

Their research will focus on improving the quality of life of those already living with Alzheimer’s disease and other forms of dementia.

The Alzheimer's Association funds independent investigators worldwide, they have awarded over $335 million to more than 2,250 projects.

Research conducted by the Alzheimer's Society, shows that there will be 850,000 people living with dementia in the UK by 2015. This will cost the UK £26 billion a year.

Two-thirds (£17.4 billion) of the cost of dementia is paid by people with dementia and their families, either in unpaid care (£11.6 billion) or in paying for private social care. This is in contrast to other conditions, such as heart disease and cancer, where the NHS provides care that is free at the point of use.


  • Promotion, prevention and eradication of the stigma associated with mental disorders Research
  • Training of healthcare professionals 
  • Better harmonization and integration between health and social care 
  • Drug treatment and therapies
  • Mental healthcare

Alzheimer Association & Societies around the Globe

  • Alzheimer's Society
  • Alzheimer's Association Spanish
  • Alzheimer's Family Support Group
  • Alzheimer's disease Chinese
  • Dementia Action Alliance
  • Lewy Body Society
  • Barbados Alzheimer's Association Inc.

Why Barcelona?

Barcelona, the cosmopolitan capital of Spain’s Catalonia region, is defined by quirky art and architecture, imaginative food and vibrant street life. It has medieval roots, seen in the mazelike Gothic Quarter, but a modernist personality represented by architect Antoni Gaudí’s fantastical Sagrada Família church. Its restaurant scene, anchored by the central Boqueria market, ranges from fine dining to tiny tapas bars. The European Prevention of Alzheimer’s Dementia (EPAD) is an initiative that groups together 36 academic research centres & universities, biotech & pharmaceutical companies and patient associations with the aim of establishing an infrastructure to facilitate clinical trials to prevent the onset of the disease.
The first volunteers, from Edinburgh and Barcelona, are currently being incorporated into the European cohort study. Some of these volunteers will later participate in an investigational clinical trial.
One of the studies promoted by the EPAD initiative includes the Barcelonabeta Brain Research Center of the Pasqual Maragall Foundation. This study will assess how the risk of developing the disease should be communicated to healthy persons or to individuals with very early symptoms.

Alzheimer’s disease is a progressive degenerative disease which causes loss of neurons in the brain. The symptoms eventually and inevitably manifest as Alzheimer’s dementia which impacts cognition, function and behaviour, becomes progressively worse over time and cannot be reversed. There are 7.7 million new cases of dementia globally each year, suggesting one new case every four seconds. There were an estimated 44.4 million people with dementia in 2013 and this number is estimated to increase to 135.5 million by 2050 

Currently approved treatments may temporarily stabilise or slow the worsening of symptoms, but do not alter the course of the disease. Attempts to bring new drugs to market for the treatment and prevention of Alzheimer’s dementia have been disappointing despite massive commercial, public and academic investment of time and resources.

Target Audience:

Neurologists and Directors, Physicians, Neuroscientists, Specialists, researchers, health care professionals, Professors, Lecturers and Students from Academia in the study of Dementia.

Around 55 associations of Vascular Dementia are there in Spain

Research into dementia in Spain comes under the neurodegenerative diseases strand of the national plan on neuroscience managed by the National Centre for Research into Neurological Disease (CIEN11 ), which comes under the control of the Ministry of Science and Innovation.

In 2008, the Spanish Ministry of Health and the non-profit Queen Sofia Foundation12 jointly established an Alzheimer’s disease research centre as part of the Alzheimer’s project.

In 2009, CIEN and the Institute of Health Carlos III13 (Spain’s public health research institute) joined forces with the Queen Sofia Foundation to create a research unit dedicated to Alzheimer’s disease and related conditions14 . In addition, the Queen Sofia Foundation and the Pasqual Maragall Foundation for Research on Alzheimer’s disease15 have launched a joint initiative to make 2011 the “year of Alzheimer’s research”16 in order to raise (private) funds, exchange ideas, and contribute towards the European initiative on Alzheimer’s disease.

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date November 07-08, 2016
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity Closed Day 1
Poster Opportunity Closed Click Here to View